| Tiffany Washechek, MD | |
|
300 S Byron Blvd, Chamberlain, SD 57325-9741 | |
| (605) 234-6551 | |
| (605) 234-7260 |
| Full Name | Tiffany Washechek |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 300 S Byron Blvd, Chamberlain, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528011590 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 5408 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tiffany Washechek, MD 300 S Byron Blvd, Chamberlain, SD 57325-9741 Ph: (605) 234-6551 | Tiffany Washechek, MD 300 S Byron Blvd, Chamberlain, SD 57325-9741 Ph: (605) 234-6551 |
News Archive
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced awards to establish four Cooperative Research Centers focused on developing vaccines to prevent sexually transmitted infections.
Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.
A new paper published on the preprint server medRxiv* in May 2020 reports the first evidence that vitamin D deficiency and inadequate treatment could increase the chances of testing positive for COVID-19. This could shape the way for screening individuals at risk for vitamin D deficiency.
A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.
› Verified 1 days ago
Cynthia L Davis, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 300 S Byron Blvd, Chamberlain, SD 57325 Phone: 605-234-6551 Fax: 605-234-7260 | |
Patricia Giebink, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 300 S Byron Blvd, Chamberlain, SD 57325 Phone: 605-234-6551 Fax: 605-234-7260 | |
James Allen Wagner, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 300 S Byron Blvd, Chamberlain, SD 57325 Phone: 605-234-6551 Fax: 605-234-7260 |